Organization
BioCryst Pharmaceuticals
11 clinical trials
Clinical trial
A Phase 3 Study to Evaluate the Safety and Pharmacokinetics of Berotralstat Prophylaxis in Children With Hereditary Angioedema Who Are 2 to < 12 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
An Open-label Study to Evaluate the Long-term Safety of BCX9930 Monotherapy in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Previously Received BCX9930 in a BioCryst-sponsored StudyStatus: Active (not recruiting), Estimated PCD: 2026-02-01
Clinical trial
A Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor TherapyStatus: Terminated, Estimated PCD: 2023-09-14
Clinical trial
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of PNHStatus: Terminated, Estimated PCD: 2023-09-14
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary AngioedemaStatus: Completed, Estimated PCD: 2019-04-10
Clinical trial
A Phase 2, Open-Label Study to Evaluate the Long-term Safety of Oral BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)Status: Terminated, Estimated PCD: 2023-10-04
Clinical trial
An Open-Label, Multicenter, Intra-Subject Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Therapeutic Potential of BCX10013 in Subjects With Paroxysmal Nocturnal HemoglobinuriaStatus: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
An Open-label Study to Provide Berotralstat Access to Subjects With Type 1 and 2 Hereditary Angioedema Who Were Previously Enrolled in Berotralstat StudiesStatus: Active (not recruiting), Estimated PCD: 2026-08-01
Clinical trial
An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary AngioedemaStatus: Completed, Estimated PCD: 2022-04-27
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary AngioedemaStatus: Completed, Estimated PCD: 2019-11-15
Clinical trial
An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects With Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous NephropathyStatus: Terminated, Estimated PCD: 2022-09-23